Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

This registry is collecting real-world data on patients with advanced melanoma (stage III or IV) who received immunotherapy before surgery (neoadjuvant immunotherapy) to see how well this approach works outside of clinical trial conditions. **You may be eligible if...** - You have operable metastatic melanoma (stage III or IV) - You received immunotherapy (anti-PD1 alone or combined with anti-CTLA-4) before surgery - This is the case even if surgery was ultimately cancelled because the cancer responded completely, progressed, or you chose not to proceed - The pathological response to the immunotherapy has been assessed **You may NOT be eligible if...** - You have a different type of cancer (not melanoma) - You did not receive neoadjuvant (pre-surgery) immunotherapy - Your pathological response to treatment has not been evaluated - You did not have stage III or IV melanoma at the time of treatment Talk to your doctor to see if this trial is right for you.